The European Medicines Agency paved the way on Friday for the use of another drug to treat Alzheimer's disease.
After review, the agency's Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization in the European Union for the antibody donanemab to treat early-stage Alzheimer's disease.
In Germany alone, approximately 1.2 million people suffer from Alzheimer's, but it is estimated that the active ingredient in the new treatment is only suitable for about 10 percent of them.
The drug cannot stop or cure Alzheimer's, but it can slow the progression of the disease in its early stages.
The European Commission now has to decide whether and when donanemab can be used in the European Union.
The drug has already been approved in the United States, Japan, China, and the United Kingdom under the brand name Kysonla.
If Brussels follows the EMA's recommendation, donanemab will be the second antibody drug approved in the EU for the treatment of Alzheimer's disease.
0 Comments